Introduction
Anti-Human CD274/PD-L1/B7-H1 Monoclonal Antibody, 2.7A4 is a type of monoclonal antibody that specifically targets and binds to the protein CD274, also known as programmed death-ligand 1 (PD-L1) or B7-H1. This protein is expressed on the surface of various cells, including cancer cells, and plays a critical role in regulating immune responses. In this article, we will provide a scientific description of the structure, activity, and potential applications of this antibody.
Structure of Anti-Human CD274/PD-L1/B7-H1 Monoclonal Antibody, 2.7A4
Anti-Human CD274/PD-L1/B7-H1 Monoclonal Antibody, 2.7A4 is a fully humanized monoclonal antibody, meaning it is derived from human cells and has a high affinity and specificity for its target. It is composed of two heavy chains and two light chains, which are linked together by disulfide bonds to form a Y-shaped structure. The variable regions of the antibody, which are responsible for binding to CD274, are located at the tips of the Y-shaped structure.
Activity of Anti-Human CD274/PD-L1/B7-H1 Monoclonal Antibody, 2.7A4
The main activity of Anti-Human CD274/PD-L1/B7-H1 Monoclonal Antibody, 2.7A4 is to block the interaction between CD274 and its receptor, PD-1, on the surface of immune cells. This interaction is known to inhibit the activation and function of T cells, a type of immune cell that plays a crucial role in fighting against cancer cells. By blocking this interaction, the antibody can enhance the anti-tumor immune response and potentially lead to the destruction of cancer cells.
Therapeutic Target
The therapeutic target of Anti-Human CD274/PD-L1/B7-H1 Monoclonal Antibody, 2.7A4 is CD274, also known as PD-L1. This protein is overexpressed in various types of cancer, including lung, breast, and bladder cancer, and is associated with poor prognosis and resistance to traditional cancer therapies. By targeting CD274, the antibody can potentially be used as a treatment for these types of cancer.
Research Use
In addition to its potential as a therapeutic target, Anti-Human CD274/PD-L1/B7-H1 Monoclonal Antibody, 2.7A4 is also widely used in research. It can be used in laboratory experiments to study the role of CD274 in immune responses and cancer development. The antibody can also be used in diagnostic tests to detect the expression of CD274 in cancer cells, which can help in determining the most effective treatment for individual patients.
Applications of Anti-Human CD274/PD-L1/B7-H1 Monoclonal Antibody, 2.7A4
The potential applications of Anti-Human CD274/PD-L1/B7-H1 Monoclonal Antibody, 2.7A4 are vast. As mentioned, it can be used as a therapeutic agent for various types of cancer, either alone or in combination with other treatments. The antibody has shown promising results in clinical trials for the treatment of lung cancer, and ongoing research is exploring its potential in other types of cancer.
Moreover, the antibody can also be used in combination with other immunotherapies, such as checkpoint inhibitors, to enhance their effectiveness. It can also be used in combination with chemotherapy or radiation therapy to overcome resistance and improve treatment outcomes.
Additionally, Anti-Human CD274/PD-L1/B7-H1 Monoclonal Antibody, 2.7A4 has potential applications in autoimmune diseases, as CD274 plays a role in regulating immune responses in these conditions.
There are no reviews yet.